Wyeth Pharmaceuticals

Huntercombe Lane South, Taplow, Maidenhead, Berks, SL6 0PH
Telephone: +44 (0)1628 604 377
Fax: +44 (0)1628 666 368
Medical Information Direct Line: +44 (0)845 367 0098
Medical Information e-mail: ukmedinfo@wyeth.com
Medical Information Fax: +44 (0)845 367 0777
Summary of Product Characteristics last updated on the eMC: 17/06/2009
SPC Premique Low Dose 0.3mg/1.5mg Modified Release Tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 17/06/2009 and displayed until Current
Reasons for adding or updating:
  • Change to section 1 -Name of the Medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   08-Jun-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 1

Premique Low Dose 0.3 mg/1.5 mg coated tablets.

Premique Low Dose 0.3mg/1.5mg modified release tablets



Section 2

Premique Low Dose 0.3 mg/1.5 mg coated tablets modified release tablets are for oral administration containing conjugated estrogens0.3 mg and medroxyprogesterone acetate (MPA) 1.5 mg.


Section 3

Coated tablet.

Modified release tablet.


Section 10

22 July 2008  08 June 2009

Updated on 12/08/2008 and displayed until 17/06/2009
Reasons for adding or updating:
  • Change to section 4.9 - Overdose
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable Effects
Date of revision of text on the SPC:   22-Jul-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company


Section 4.2
New wording added under subheading 'Maintenance/Continuation/Extended Treatment'

Section 4.8
Table revised and additional side effects added

Section 4.9
Wording updated in line with global company prescribing information
Updated on 11/06/2008 and displayed until 12/08/2008
Reasons for adding or updating:
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 6. 4 - Special Precautions for Storage
Date of revision of text on the SPC:   23-May-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 6.4

The following sentence has been added 'Keep blister in the outer carton to protect from light.'

Section 6.5

The following text replaces current packaging information:  'Each carton contains 28 tablets (1 blister pack) or  84 tablets (3 blister packs).Not all pack sizes may be marketed.'
Updated on 07/05/2008 and displayed until 11/06/2008
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   15-Apr-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Section 4.2  (Posology and method of administration) the following text has been added:  Patients should be re-evaluated periodically to determine if treatment for symptoms is still necessary.

Section 10 (DATE OF REVISION OF THE TEXT) the date has been amended to:  
15th April 2008

Updated on 20/09/2006 and displayed until 07/05/2008
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 15/09/2006 and displayed until 20/09/2006
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 10/02/2006 and displayed until 15/09/2006
Reasons for adding or updating:
  • Change to section 4.1 - Therapeutic Indications
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 10 (date of (partial) revision of the text
  • Change to section 4.8 - Undesirable Effects
Updated on 10/05/2004 and displayed until 10/02/2006
Reasons for adding or updating:
  • New SPC for new product

Active Ingredients/Generics

 
   medroxyprogesterone acetate
   oestrogens, conjugated


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk